Vitamin D has two forms: ergocalciferol (vitamin D~2~) is synthesized *via* UV irradiation of ergosterol, a steroid found in fungi and some plants, whereas cholecalciferol (vitamin D~3~) is synthesized via UV irradiation of 7-dehydrocholesterol to previtamin D~3~, followed by a thermal isomerization step. In humans, the source of vitamin D~3~ may be endogenous (*i.e.,* obtained via cutaneous synthesis) or exogenous (*i.e.,* ingested in foods or supplements), whereas vitamin D~2~ is only available from exogenous sources. Vitamin D~2~ and vitamin D~3~ are structurally distinct: the side chain of vitamin D~2~ contains a double bond between carbons 22 and 23 and a methyl group on carbon 24, both of which are absent from the side chain of vitamin D~3~. The two forms also have differing pharmacokinetics: of 14 publications comparing effects of vitamin D~2~ vs vitamin D~3~ ([@bib1]--[@bib14]), all but three ([@bib12]--[@bib14]) reported that vitamin D~2~ was less effective than vitamin D~3~ in elevating total 25(OH)D levels. A meta-analysis of data from seven of these studies found that this effect was only statistically significant when vitamin D was administered using intermittent bolus dosing, as opposed to daily administration ([@bib15]). 25-hydroxyvitamin D~3~ \[25(OH)D~3~\] subsequently undergoes a second hydroxylation step to form the active vitamin D metabolite 1*α*,25-dihydroxyvitamin D~3~ \[1*α*,25(OH)~2~D~3~\] or the inactive metabolites 24R,25-dihydroxyvitamin D~3~ \[24R,25(OH)~2~D~3~\] and 4*β*,25-dihydroxyvitamin D \[4*β*,25(OH)~2~D~3~; [Fig. 1](#fig1){ref-type="fig"}\]. It also undergoes conjugation to circulating inactive sulfate and glucuronide metabolites that may be recycled back to 25(OH)D~3~ rather than excreted ([@bib16], [@bib17]).

![Vitamin D~3~ oxidation pathways. The monohydroxylated and dihydroxylated metabolites investigated in the current study are shown, with the cytochrome P450 enzymes catalyzing each conversion in capitals.](jc.2019-00207f1){#fig1}

Administration of vitamin D~2~ has been reported to reduce circulating concentrations of 25(OH)D~3~ in eight studies ([@bib1]--[@bib7], [@bib11]); a ninth study reports a nonstatistically significant trend in the same direction ([@bib12]). These observations have led investigators to speculate that vitamin D~2~ may influence metabolism of vitamin D~3~. In keeping with this hypothesis, a recent study reported that administration of vitamin D~2~ increases the ratio of 24R,25(OH)~2~D~3~ to 25(OH)D~3~ in the circulation and decreases the ratio of 1*α*,25\[OH\]~2~D~3~ to 25(OH)D~3~, findings taken to indicate that vitamin D~2~ induces 24R-hydroxylation and suppresses 1*α*-hydroxylation of 25(OH)D~3~ ([@bib18]). However, it is not yet known if these effects are vitamin D~2~-specific, because administration of vitamin D~3~ also influences the rate of conversion of parent vitamin D~3~ to its hydroxylated metabolites ([@bib19]). Moreover, the influence of administering vitamin D~2~ on circulating concentrations of vitamin D~3~ and 4*β*,25(OH)~2~D~3~ has yet to be determined.

Studies making a head-to-head comparison of the influence of identical doses of vitamin D~2~ vs vitamin D~3~ on circulating concentrations of vitamin D~3~, 25(OH)D~3~ and its major dihydroxylated metabolites are needed to resolve these questions. An opportunity to conduct such an investigation recently arose in the context of a randomized controlled trial that we conducted in the United Kingdom to evaluate the effect of administration of four monthly oral doses of 2.5 mg vitamin D~2~ vs the same dose of vitamin D~3~ on glycated hemoglobin concentration among people at risk for type 2 diabetes mellitus ([@bib11]). We therefore determined concentrations of vitamin D~3~, 25(OH)D~3~, 24R,25(OH)~2~D~3~, 1*α*,25(OH)~2~D~3~, and 4*β*,25(OH)~2~D~3~ in serum samples taken from a subset of trial participants before and after administration of vitamin D~2~ vs vitamin D~3~, and calculated the change in postsupplementation metabolite-to-parent ratios to gain insight into the relative effects of vitamin D~2~ vs vitamin D~3~ on the activity of enzymes catalyzing 25-hydroxylation of vitamin D~3~ and 1*α*-hydroxylation, 24R-hydroxylation, and 4*β*-hydroxylation of 25(OH)D~3~. We also measured concentrations of vitamin D~2~ and 25(OH)D~2~ in the same samples and compared the influence of vitamin D~2~ vs vitamin D~3~ on 25-hydroxylation of vitamin D~2~.

Methods {#s6}
=======

Trial design and participants {#s7}
-----------------------------

As previously described, we conducted a double-blind, randomized placebo-controlled trial that enrolled a total of 340 men and women aged 30 to 75 years who had been identified as being at increased risk of developing type 2 diabetes mellitus in London and Cambridge, United Kingdom ([@bib11]). Full details of inclusion and exclusion criteria are described in the published protocol ([@bib20]). Eligible participants were randomly allocated to one of three groups on a 1:1:1 basis within four strata defined by age (30 to 50 or 51 to 75 years) and sex, with a block size of six within each stratum. One group received four monthly oral bolus doses of 2.5 mg vitamin D~2~: each dose was presented as 5 mL Sterogyl solution (Desma Pharma, Paris, France) containing 0.5 mg vitamin D~2~ per milliliter in ethanol. The second group received four monthly oral bolus doses of 2.5 mg vitamin D~3~: each dose was presented as 5 mL Vigantol oil (Merck Serono, Darmstadt, Germany) containing 0.5 mg vitamin D~3~ per milliliter in Miglyol oil (Caesar & Loretz, Hilden, Germany). The third group received four monthly oral doses of placebo (Miglyol oil). The order of treatments within each block was determined by a computer-generated pseudo-random sequence, generated by the study medication manufacturer (Nova Laboratories, Leicester, UK). Neither the participants, the investigators, nor the laboratory staff knew the treatment allocation. Each participant was followed-up for a total of four months from their first visit; serum samples were collected at baseline and at the end of the study. Baseline and four-month serum samples taken from a subset of 28 participants and allocated to vitamin D~2~ and 25 participants allocated to vitamin D~3~ were sent for determination of concentrations of vitamin D~3~ and its metabolites as detailed below. The subset of participants contributing samples to the current study were selected on the basis that they were all recruited in London; that they had each received four directly observed doses of vitamin D~2~ or vitamin D~3~; and that they were the 28 samples in each group having the greatest volume of serum available at both baseline and four-month follow-up to be sent for further analysis. For the vitamin D~3~ group, only 25 samples had sufficient sample volume for analysis. Ethical approval for the trial was provided by the Charing Cross Medical Ethics Committee (ref 09/H0711/85) and the Cambridge Local Research Ethics Committee (ref 04/Q0108/19), and written informed consent was obtained from all participants. The trial was registered under the numbers EudraCT 2009-011264-11 and ISRCTN86515510 on 23 October 2009.

Laboratory assays {#s8}
-----------------

Serum concentrations of vitamin D~3~, vitamin D~2~, 25(OH)D~3~, 25(OH)D~2~, 24R,25(OH)~2~D~3~, 1*α*,25(OH)~2~D~3~, 1*α*,25(OH)~2~D~2~, and 4*β*,25(OH)~2~D~3~ were determined by liquid chromatography-tandem mass spectrometry in the Thummel Laboratory, Department of Pharmaceutics, University of Washington, Seattle, Washington, as previously described ([@bib21]). Lower limits of quantitation (LLOQ) were 0.23 nmol/L for vitamin D~3~, 0.15 nmol/L for vitamin D~2~, 0.50 nmol/L for 25(OH)D~3~, 0.24 nmol/L for 25(OH)D~2~, 0.14 nmol/L for 24R,25(OH)~2~D~3~, and 7.7 pmol/L for 1*α*,25(OH)~2~D~3~, 1*α*,25(OH)~2~D~2~ and 4*β*,25(OH)~2~D~3~. Where concentrations of a given analyte were less than the LLOQ, a value equal to the LLOQ divided by the √2 was imputed, as performed elsewhere ([@bib22]). Intraday and interday coefficients of variation were \<15% for all analytes, as previously reported ([@bib21]).

Sample size and statistical analyses {#s9}
------------------------------------

We estimated that paired before and after serum samples from 21 participants would need to be evaluated to have 90% power to detect a 15 nmol/L difference in 25(OH)D~3~ concentration preadministration vs postadministration of vitamin D~2~ with *α* = 0.05, based on a standard deviation for postsupplementation serum 25(OH)D~3~ concentration of 20 nmol/L ([@bib11]). This sample size was inflated to 28 to allow for potential assay failure. Serum samples from a similar number of participants allocated to vitamin D~3~ were also evaluated.

Statistical analyses were conducted using GraphPad Prism version 6.04 (GraphPad Software Inc., La Jolla, CA) and STATA IC version 12 (StataCorp, College Station, TX). Intragroup differences in absolute concentrations of vitamin D~3~ and its metabolites before vs after supplementation with vitamin D~2~ or vitamin D~3~ were evaluated using paired Student *t* tests. Intergroup differences in end-study values of these parameters were evaluated with linear regression, adjusting for baseline values. Mean differences are presented with 95% CI and *P* values, with statistical significance inferred where *P* values are less than 0.05.

Results {#s10}
=======

Participant enrollment and baseline characteristics {#s11}
---------------------------------------------------

A total of 340 adults were randomly assigned to receive supplementation with vitamin D~2~ (n = 112) vs vitamin D~3~ (n = 114) vs placebo (n = 114) between 2010 and 2012, of whom 285 (94 randomized to vitamin D~2~ vs 99 randomized to vitamin D~3~ vs 92 randomized to placebo) took all four doses of study medication and completed follow-up. For the current study, baseline and four-month serum samples collected from a subset of participants recruited in London who took four doses of vitamin D~2~ (n = 28) or vitamin D~3~ (n = 25) were sent for determination of concentrations of vitamin D and its metabolites ([Fig. 2](#fig2){ref-type="fig"}). Effects of the intervention on the primary outcome of the main trial, and on safety, are reported elsewhere ([@bib11]). The trial ended on the date of the final study visit of the last participant to be randomized. One participant selected for the substudy and randomly assigned to vitamin D~3~ was found to have a high outlying baseline 25(OH)D~2~ concentration (51.8 nmol/L) and was excluded from statistical analyses at a reviewer's request. Baseline characteristics of participants whose serum samples contributed to the current study are presented in [Table 1](#tbl1){ref-type="table"}. Overall, mean age was 55.6 years (SD 10.0 years) and 21 of 52 (40.4%) participants were female. Baseline demographic and clinical characteristics, serum concentrations of vitamin D~3~, vitamin D~2~ and their metabolites and metabolite-to-parent ratios were similar for those randomized to receive vitamin D~2~ vs vitamin D~3~ where measurable; concentrations of 1*α*,25(OH)~2~D~2~ were undetectable (\<7.7 pmol/L) in all samples.

![Trial profile.](jc.2019-00207f2){#fig2}

###### 

Participants' Baseline Characteristics by Allocation

                                                                                                    Characteristics                                                          Vitamin D~2~ (n=28)                              Vitamin D~3~ (n = 24)
  ------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------ ------------------------------------------------ -----------------------------------------------
  Sex                                                                                               Female, n (%)                                                            10 (35.7)                                        11 (45.8)
                                                                                                    Male, n (%)                                                              18 (64.3)                                        13 (54.2)
  Mean age, y (SD)                                                                                  56.0 (10.8)                                                              55.0 (9.1)                                       
  Ethnic origin                                                                                     White, n (%)                                                             18 (64.3)                                        18 (75.0)
                                                                                                    Other, n (%)                                                             10[^*a*^](#tblfn1){ref-type="table-fn"} (35.7)   6 (25.0)[^*b*^](#tblfn2){ref-type="table-fn"}
  Total serum concentration of vitamin D and its metabolites[^*c*^](#tblfn3){ref-type="table-fn"}   Mean total vitamin D, nmol/L (SD)[^*d*^](#tblfn4){ref-type="table-fn"}   6.5 (6.7)                                        8.6 (8.5)
  Mean total 25(OH)D, nmol/L (SD)[^*e*^](#tblfn5){ref-type="table-fn"}                              49.7 (32.3)                                                              45.5 (25.0)                                      
  Mean total 25(OH)D-to-total vitamin D molar ratio (SD)                                            19.3 (27.5)                                                              18.6 (22.4)                                      
  Serum concentration of vitamin D~3~ and its metabolites                                           Mean vitamin D~3~, nmol/L (SD)                                           2.9 (3.3)                                        3.5 (4.2)
  Mean 25(OH)D~3~, nmol/L (SD)                                                                      46.1 (32.4)                                                              42.0 (24.7)                                      
  Mean 1*α*,25(OH)~2~D~3~, pmol/L (SD)                                                              77.2 (46.0)                                                              96.9 (55.1)                                      
  Mean 24R,25(OH)~2~D~3~, nmol/L (SD)                                                               3.2 (2.7)                                                                2.9 (1.8)                                        
  Mean 4*β*,25(OH)~2~D~3~, pmol/L (SD)                                                              126.4 (133.8)                                                            97.1 (104.9)                                     
  Mean 25(OH)D~3~-to-vitamin D~3~ molar ratio (SD)                                                  39.0 (47.2)                                                              34.1 (44.2)                                      
  Mean 24R,25(OH)~2~D~3~-to-25(OH)D~3~ molar ratio (SD)                                             0.07 (0.03)                                                              0.07 (0.04)                                      
  Mean 1*α*,25(OH)~2~D~3~-to-25(OH)D~3~ molar ratio (SD)                                            0.0023 (0.0018)                                                          0.0029 (0.0022)                                  
  Mean 4*β*,25(OH)~2~D~3~-to-25(OH)D~3~ molar ratio (SD)                                            0.0024 (0.0016)                                                          0.0020 (0.0014)                                  
  Serum concentration of vitamin D~2~ and its metabolites                                           Mean vitamin D~2~, nmol/L (SD)                                           3.6 (5.3)                                        5.1 (7.7)
  Mean 25(OH)D~2~, nmol/L (SD)                                                                      3.5 (1.3)                                                                3.5 (1.5)                                        
  Mean 1*α*,25(OH)~2~D~2~, pmol/L, (SD)                                                             \<7.7[^*f*^](#tblfn6){ref-type="table-fn"}                               \<7.7[^*f*^](#tblfn6){ref-type="table-fn"}       
  Mean 25(OH)D~2~-to-vitamin D~2~ molar ratio (SD)                                                  18.5 (17.2)                                                              16.2 (19.5)                                      

Of whom 6 were of black or black British ethnic origin and 4 were of Asian or Asian British ethnic origin.

Of whom 5 were of Asian or Asian British ethnic origin and 1 was of black or black British ethnic origin.

Not calculated for 1,25-dihydroxyvitamin D (1,25-dihydroxyvitamin D~2~ was undetectable in all) or 24,R,25-dihydroxyvitamin D/4*β*-dihydroxyvitamin D (neither 24,R,25-dihydroxyvitamin D~2~ nor 4*β*-dihydroxyvitamin D~2~ were measured).

Calculated by summing values for vitamin D~2~ and vitamin D~3.~

Calculated by summing values for 25-hydroxyvitamin D~2~ and 25-hydroxyvitamin D~3.~

1*α*,25(OH)~2~D~2~ undetectable in all; lower limit of quantification for this metabolite was 7.7 pmol/L.

Influence of vitamin D~2~ vs vitamin D~3~ on total 25(OH)D concentrations {#s12}
-------------------------------------------------------------------------

Both vitamin D~2~ and vitamin D~3~ elevated total 25(OH)D concentrations at follow-up: the mean increase in total 25(OH)D concentrations after administration of vitamin D~2~ was 31.4 nmol/L (95% CI 21.5 to 41.2 nmol/L, *P* \< 0.001), and the corresponding increase in total 25(OH)D concentrations after administration of vitamin D~3~ was 46.4 nmol/L (95% CI 33.7 to 59.0 nmol/L, *P* \< 0.001). The difference in the mean change in total 25(OH)D concentration at follow-up for participants randomized to vitamin D~3~ vs vitamin D~2~ was 13.0 nmol/L (95% CI -0.5 to 26.6 nmol/L, *P* = 0.06; [Table 2;](#tbl2){ref-type="table"}[Fig. 3](#fig3){ref-type="fig"}). No difference in the ratio of total 25(OH)D to total parent vitamin D at follow-up was seen between participants randomized to vitamin D~2~ vs vitamin D~3~ (*P* = 0.32).

###### 

Serum Concentrations of Vitamin D~3~, Vitamin D~2~ and Their Metabolites After Administration of Vitamin D~2~ vs Vitamin D~3~

                                                                             Post-Vitamin D~2~ (n = 28)   Post-Vitamin D~3~ (n = 24)                    Paired Analyses                Unpaired Analysis                                                                        
  -------------------------------------------------------------------------- ---------------------------- --------------------------------------------- ------------------------------ ------------------- ----------------------------- --------- ---------------------------- ---------
  Total vitamin D and its metabolites[^*b*^](#tblfn8){ref-type="table-fn"}                                                                                                                                                                                                      
   Mean total vitamin D, nmol/L (SD)[^*c*^](#tblfn9){ref-type="table-fn"}    7.4 (7.8)                    6.8 (5.7)                                     0.9 (−3.1 to 5.0)              0.65                −1.7 (−5.8 to 2.3)            0.39      −0.6 (−4.6 to 3.3)           0.75
   Mean total 25(OH)D, nmol/L (SD) [^*d*^](#tblfn10){ref-type="table-fn"}    81.0 (21.9)                  91.9 (34.5)                                   31.4 (21.5 to 41.2)            \<0.001             46.4 (33.7 to 59.0)           \<0.001   13.0 (−0.5 to 26.6)          0.06
   Mean total 25(OH)D-to-total vitamin D molar ratio (SD)                    27.8 (49.1)                  17.6 (7.9)                                    8.5 (−13.9 to 31.0)            0.44                −1.1 (−10.2 to 8.1)           0.81      −10.3 (−30.9 to 10.3)        0.32
  Vitamin D~3~ and its metabolites                                                                                                                                                                                                                                              
  Mean vitamin D~3~, nmol/L (SD)                                             5.6 (7.3)                    6.3 (5.5)                                     2.7 (−0.3 to 5.8)              0.07                2.8 (0.3 to 5.3)              0.03      0.5 (−3.2 to 4.1)            0.80
   Mean 25(OH)D~3~, nmol/L (SD)                                              26.2 (19.1)                  88.2 (34.1)                                   −19.9 (−29.3 to −10.5)         \<0.001             46.2 (33.3 to 59.2)           \<0.001   64.0 (51.0 to 77.1)          \<0.001
   Mean 24R,25(OH)~2~D~3~, nmol/L                                            2.0 (1.5)                    7.7 (3.0)                                     −1.2 (−2.0 to −0.3)            0.007               4.8 (3.7 to 6.0)              \<0.001   5.8 (4.7 to 7.0)             \<0.001
   Mean 1*α*,25(OH)~2~D~3~, pmol/L                                           36.0 (50.5)                  161.4 (95.4)                                  −41.1 (−63.8 to 18.5)          \<0.001             64.5 (21.4 to 107.6)          0.005     119.7 (77.6 to 161.8)        \<0.001
   Mean 4*β*,25(OH)~2~D~3~, pmol/L                                           73.2 (81.9)                  305.4 (438.6)                                 −53.2 (−99.2 to −7.2)          0.03                208.3 (40.7 to 375.9)         0.02      258.8 (98.0 to 419.7)        0.002
   Mean 25(OH)D~3~-to-vitamin D~3~ molar ratio (SD)                          9.3 (11.4)                   18.2 (7.7)                                    −29.7 (−48.5 to −10.9)         0.003               −15.9 (−34.5 to 2.7)          0.09      9.0 (3.4 to 14.6)            0.002
   Mean 24R,25(OH)~2~D~3~-to-25(OH)D~3~ molar ratio (SD)                     0.0822 (0.0435)              0.0928 (0.0297)                               0.0163 (0.0010 to 0.0315)      0.04                0.0214 (0.0069 to 0.0360)     0.006     0.0078 (−0.0114 to 0.0270)   0.42
   Mean 1*α*,25(OH)~2~D~3~-to-25(OH)D~3~ molar ratio (SD)                    0.0011 (0.0015)              0.0020 (0.0011)                               −0.0012 (−0.0022 to −0.0002)   0.02                −0.0009 (−0.0020 to 0.0001)   0.06      0.0009 (0.0001 to 0.0017)    0.03
   Mean 4*β*,25(OH)~2~D~3~-to-25(OH)D~3~ molar ratio (SD)                    0.0024 (0.0022)              0.0030 (0.0027)                               0.0000 (−0.0009 to 0.0009)     0.97                0.0010 (−0.0001 to 0.0021)    0.06      0.0008 (−0.0006 to 0.0021)   0.25
  Vitamin D~2~ and its metabolites                                                                                                                                                                                                                                              
   Mean vitamin D~2~, nmol/L (SD)                                            1.8 (1.1)                    0.6 (0.8)                                     −1.8 (−4.0 to 0.3)             0.09                −4.5 (−7.7 to −1.3)           0.008     −1.2 (−1.8 to −0.6)          \<0.001
   Mean 25(OH)D~2~, nmol/L (SD)                                              54.8 (12.9)                  3.6 (1.5)                                     51.2 (46.2 to 56.3)            \<0.001             0.1 (−0.5--0.7)               0.64      −51.1 (-56.5 to −45.7)       \<0.001
   Mean 1*α*,25(OH)~2~D~2~, pmol/L                                           \<7.7^*e*^                   \<7.7[^*e*^](#tblfn11){ref-type="table-fn"}   ---                            ---                                               ---       ---                          ---
   Mean 25(OH)D~2~-to-vitamin D~2~ molar ratio, (SD)                         111.0 (185.2)                24.6 (18.5)                                   92.5 (21.8 to 163.3)           0.01                8.4 (−0.8 to 17.7)            0.07      −83.7 (−160.0 to −7.4)       0.03

Adjusted for baseline value.

Not calculated for 1,25-dihydroxyvitamin D (1,25-dihydroxyvitamin D~2~ was undetectable in all) or 24,R,25-dihydroxyvitamin D/4*β*-dihydroxyvitamin D (neither 24,R,25-dihydroxyvitamin D~2~ nor 4*β*-dihydroxyvitamin D~2~ were measured).

Calculated by summing values for vitamin D~2~ and vitamin D~3~.

Calculated by summing values for 25-hydroxyvitamin D~2~ and 25-hydroxyvitamin D~3~.

1*α*,25(OH)~2~D~2~ undetectable in all; LLOQ for this metabolite was 7.7 pmol/L.

![Influence of oral administration of vitamin D~3~ and vitamin D~2~ on serum concentrations of (A) total 25(OH)D, (B) 25(OH)D~3~, (C) 25(OH)D~2~, and (D) 1*α*,25(OH)~2~D~3~. Baseline and 4-mo data are presented for 24 adults receiving four bolus doses of 2.5 mg vitamin D~3~ at 0, 1, 2, and 3 mo postrandomization and 28 adults receiving an equivalent regimen of vitamin D~2~. Lines link data points from the same individual; *P* values for within-group comparisons before vs after supplementation are from paired Student *t* tests. *P* values for intergroup comparisons of postsupplementation values in participants randomized to vitamin D~3~ vs vitamin D~2~ are from linear regression with adjustment for baseline values.](jc.2019-00207f3){#fig3}

Influence of vitamin D~2~ on metabolism of vitamin D~3~ {#s13}
-------------------------------------------------------

To characterize effects of vitamin D~2~ on metabolism of D~3~, we conducted pairwise statistical analyses comparing circulating concentrations of vitamin D~3~ and its metabolites in 28 individuals before vs after oral administration of four monthly doses of 2.5 mg vitamin D~2~. Results are presented in [Table 2](#tbl2){ref-type="table"}. Administration of vitamin D~2~ had no statistically significant effect on serum concentrations of vitamin D~3~ (*P* = 0.07), but it did reduce mean serum concentrations of 25(OH)D~3~ (43.2% decrease, *P* \< 0.001; [Fig. 3](#fig3){ref-type="fig"}), 24R,25(OH)~2~D~3~ (37.5% decrease, *P* = 0.007), 1*α*,25(OH)~2~D~3~ (53.4% decrease, *P* \< 0.001; [Fig. 3](#fig3){ref-type="fig"}) and 4*β*,25(OH)~2~D~3~ (42.0% decrease, *P* = 0.03). Administration of vitamin D~2~ reduced molar ratios of 25(OH)D~3~ to vitamin D~3~ (76.2% decrease, *P* = 0.003) and 1*α*,25(OH)~2~D~3~ to 25(OH)D~3~ (52.2% decrease, *P* = 0.02), but increased the molar ratio of 24R,25(OH)~2~D~3~ to 25(OH)D~3~ (24.5% increase, *P* = 0.04). No statistically significant effect of vitamin D~2~ on the molar ratio of 4*β*,25(OH)~2~D~3~ to 25(OH)D~3~ was seen (*P* = 0.97).

Influence of vitamin D~3~ on its own metabolism {#s14}
-----------------------------------------------

Having characterized the effects of vitamin D~2~ on metabolism of vitamin D~3~, we proceeded to conduct a second set of pairwise before and after statistical analyses to evaluate the effects of vitamin D~3~ on the same biochemical parameters in a separate group of 24 individuals who received four monthly doses of 2.5 mg vitamin D~3~. Results of these analyses ([Table 2](#tbl2){ref-type="table"}) show that administration of vitamin D~3~ elevated serum concentrations of vitamin D~3~ (80.0% increase, *P* = 0.03), 25(OH)D~3~ (110.0% increase, *P* \< 0.001; [Fig. 3](#fig3){ref-type="fig"}), 24R,25(OH)~2~D~3~ (165.5% increase, *P* \< 0.001), 1*α*,25(OH)~2~D~3~ (66.6% increase, *P* = 0.005), and 4*β*,25(OH)~2~D~3~ (214.5% increase, *P* = 0.02). Administration of vitamin D~3~ also increased the ratio of 24R,25(OH)~2~D~3~ to 25(OH)D~3~ (32.6% increase, *P* = 0.006) but had no statistically significant effect on ratios of 25(OH)D~3~ to vitamin D~3~ (*P* = 0.09), 1*α*,25(OH)~2~D~3~ to 25(OH)D~3~ (*P* = 0.06), or 4*β*,25(OH)~2~D~3~ to 25(OH)D~3~ (*P* = 0.06).

Comparing effects of vitamin D~2~ vs vitamin D~3~ on metabolism of vitamin D~3~ {#s15}
-------------------------------------------------------------------------------

To determine whether the two forms of vitamin D exerted different effects on metabolism of vitamin D~3~, we undertook unpaired statistical analyses comparing postsupplementation values of vitamin D~3~ metabolite-to-parent ratios between individuals supplemented with vitamin D~2~ vs vitamin D~3~, using linear regression with adjustment for baseline values. Results of these analyses ([Table 2](#tbl2){ref-type="table"}) reveal that participants receiving vitamin D~2~ had lower mean postsupplementation ratios of 25(OH)D~3~ to vitamin D~3~ (*P* = 0.002) and 1*α*,25(OH)2D~3~ to 25(OH)D~3~ (*P* = 0.03) than those who received vitamin D~3~. No statistically significant difference in mean postsupplementation ratios of 24R,25(OH)~2~D~3~ to 25(OH)D~3~ (*P* = 0.42) or 4*β*,25(OH)~2~D~3~ to 25(OH)D~3~ (*P* = 0.25) was seen between participants receiving vitamin D~2~ vs vitamin D~3~.

Influence of vitamin D~3~ vs vitamin D~2~ on metabolism of vitamin D~2~ {#s16}
-----------------------------------------------------------------------

Although the primary focus of our study was to compare the effects of vitamin D~2~ vs vitamin D~3~ on metabolism of vitamin D~3~, limited data were also available to evaluate relative effects of the two forms of vitamin D on metabolism of vitamin D~2~ ([Table 2](#tbl2){ref-type="table"}). Pairwise analyses revealed that administration of vitamin D~2~ increased mean serum 25(OH)D~2~ concentration (*P* \< 0.001; [Fig. 3](#fig3){ref-type="fig"}) and mean 25(OH)D~2~-to-D~2~ molar ratio (*P* = 0.01), but had no statistically significant effect on mean serum concentration of vitamin D~2~ itself (*P* = 0.09). By contrast, administration of vitamin D~3~ reduced vitamin D~2~ concentrations over time (*P* = 0.008) but did not influence 25(OH)D~2~ concentrations (*P* = 0.64; [Fig. 3](#fig3){ref-type="fig"}) or 25(OH)D~2~-to-D~2~ ratio (*P* = 0.07). Unpaired analysis comparing postsupplementation 25(OH)D~2~-to-D~2~ ratios between individuals supplemented with vitamin D~2~ vs vitamin D~3~, with adjustment for baseline values, showed that the mean postsupplementation ratio of 25(OH)D~2~ to vitamin D~2~ among participants receiving vitamin D~2~ was higher than that of participants who received vitamin D~3~ (*P* = 0.03).

Discussion {#s17}
==========

To our knowledge, this is the first investigation to evaluate the influence of vitamin D~2~ on circulating concentrations of parent vitamin D~3~ and its dihydroxylated metabolite 4*β*,25(OH)~2~D~3~ in addition to serum concentrations of 25(OH)D~2~ and 25(OH)D~3~. We found that administration of vitamin D~2~ exerted a greater inhibitory effect than administration of vitamin D~3~ on mean ratios of 25(OH)D~3~ to D~3~ and 1*α*,25(OH)~2~D~3~ to 25(OH)D~3~ in the circulation. We also observed that vitamin D~2~ and vitamin D~3~ increased the mean 24R,25(OH)~2~D~3~-to-25(OH)D~3~ ratio to a similar extent, and that neither form of vitamin D had a statistically significant effect on the mean serum 4*β*,25(OH)~2~D~3~-to-25(OH)D~3~ ratio. By contrast with findings of a recently published study ([@bib6]), we found that administration of vitamin D~3~ did not suppress serum concentrations of 25(OH)D~2~, nor did it influence mean serum 25(OH)D~2~-to-vitamin D~2~ ratio. Administration of vitamin D~2~ resulted in an increase in the mean 25(OH)D~2~-to-D~2~ ratio.

Our findings are consistent with reports that administration of vitamin D~2~ reduces serum concentrations of 25(OH)D~3~ ([@bib1]--[@bib4]), and that this phenomenon is associated with an increase in the ratio of 24R,25(OH)~2~D~3~ to 25(OH)D~3~ and a decrease in the ratio of 1*α*,25(OH)2D~3~ to 25(OH)D~3~ in the circulation. Interestingly, serum 25(OH)D~2~ concentrations were markedly elevated in all study participants receiving vitamin D~2~, consistent with induction of the vitamin D~2~ 25-hydroxylation pathway, although there was an opposite effect on 25(OH)D~3~ and rate of formation in the same treated individuals ([Fig. 3](#fig3){ref-type="fig"}), raising the possibility that different enzymes might catalyze 25-hydroxylation of the two forms of vitamin D. Alternatively, the decline of 25(OH)D~3~ following administration of vitamin D~2~ may reflect competition of vitamin D~2~ for the same 25-hydroxylation pathway as vitamin D~3~. Although changes in metabolite-to-parent ratios may reflect alteration in rates of conversion of one metabolite to another, they could also be explained by removal of vitamin D and its metabolites from the circulation (*e.g.,* via direct excretion or disposition into depots such as adipose tissue and muscle). Further investigations to compare the effects of different forms of vitamin D on expression and activity of the enzymes responsible for metabolizing vitamin D~3~ are needed to resolve the question of whether changes in metabolite-to-parent ratios truly reflect changes in activity of cytochrome P450 enzymes. Such studies would potentially require liver and renal biopsies: both are invasive procedures and their inclusion in a study protocol could raise issues relating to ethics and acceptability to participants.

One aspect in which our findings differ from those of other investigators relates to the lack of detectable 1,25-dihydroxyvitamin D~2~ at follow-up among participants receiving vitamin D~2~ in our study. By contrast, Biancuzzo *et al.* reported that daily administration of 1,000 IU vitamin D~2~ for 11 weeks induced a mean increase in serum 1,25(OH)~2~D~2~ concentration of 5.2 pg/mL (13.5 pmol/L) ([@bib14]). This difference may reflect use of intermittent bolus dosing in the current study, which contrasts with the daily dosing regimen used by Biancuzzo *et al.*

Our findings provide insights into the differential effects of ergocalciferol and cholecalciferol on vitamin D metabolism, however, from the clinician's perspective, a key question relates to relative effects of the two forms of vitamin D on total 25(OH)D levels, which reflect vitamin D status. Among substudy participants, the mean increase in total 25(OH)D for participants randomized to vitamin D~2~ (n = 28) vs vitamin D~3~ (n = 25) was 31.4 nmol/L vs 46.4 nmol/L, respectively (*P* for intergroup comparison = 0.06). This trend is in keeping with findings from the main trial, in which the difference in increase in total 25(OH)D for participants randomized to vitamin D~2~ (n = 112) vs D~3~ (n= 114; 31.2 vs 38.3 nmol/L increase, respectively) attained statistical significance (*P* = 0.03).

Our study has several strengths. Participants randomized to vitamin D~2~ vs D~3~ were well matched with regard to baseline characteristics, and directly observed administration of vitamin D~2~ and vitamin D~3~ at identical doses via the same route allowed for a head-to-head comparison of their effects. Determination of concentrations of parent vitamin D~2~ and D~3~, 25(OH)D~2~, 25(OH)D~3~, and its major dihydroxylated metabolites allowed us to compare effects of vitamin D~2~ vs vitamin D~3~ on both the synthesis and the catabolism of 25(OH)D~3~. Moreover, we utilized the gold standard method (liquid chromatography-tandem mass spectrometry) to measure concentrations of vitamin D and its metabolites with high degrees of accuracy and sensitivity, avoiding issues of cross-reactivity between metabolites of vitamin D~2~ and vitamin D~3~ that may arise with immunoassays ([@bib23]).

Our study also has some limitations. We measured concentrations of vitamin D metabolites at a single time point, one month after the fourth bolus dose was given; thus, we do not capture the pharmacokinetics of vitamin D metabolism at multiple points over the period of the dosing interval. In particular, conclusions relating to concentrations of parent vitamin D~2~ and vitamin D~3~ in the circulation should be guarded, because of their short half-life. Participants all had an elevated risk of type 2 diabetes mellitus: thus, our findings cannot necessarily be generalized to other groups. However, we have no specific reason to believe that effects of vitamin D~2~ are likely to be different in this group compared with the general population. We did not measure concentrations of 1,24,25-trihydroxyvitamin D~3~ or 24R,25(OH)~2~D~2~: this could have provided insights into the effects of vitamin D~2~ vs vitamin D~3~ on 24-hydroxylation of 1*α*,25(OH)~2~D~3~ and 25(OH)D~2~, respectively. Preparations of vitamin D~2~ and vitamin D~3~ were presented in different vehicles (alcohol vs oily solution, respectively), which could theoretically have impacted differently on absorption and/or metabolism. However, a study in schoolchildren comparing ethanol vs oil as a vehicle for a weekly oral dose of 14,000 IU vitamin D~3~ showed no difference in the 25(OH)D response to supplementation between groups over eight weeks ([@bib24]), rendering this explanation for the findings in the current study unlikely.

In conclusion, the current study confirms reports that vitamin D~2~ is less effective than vitamin D~3~ in elevating total 25(OH)D levels, and extends prior findings by showing that administration of vitamin D~2~ reduces 25-hydroxylation of vitamin D~3~ and 1-*α* hydroxylation of 25(OH)D~3~ and increases 24R-hydroxylation of 25(OH)D~3~.
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1*α*,25(OH)~2~D~3~

:   1*α*,25-dihydroxyvitamin D~3~

4*β*,25(OH)~2~D~3~

:   4*β*,25-dihydroxyvitamin D~3~

24R,25(OH)~2~D~3~

:   24R,25-dihydroxyvitamin D~3~

25(OH)D

:   25-hydroxyvitamin D

25(OH)D~3~

:   25-hydroxyvitamin D~3~

LLOQ

:   lower limit of quantitation
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